Literature DB >> 9552993

Monitoring randomised controlled trials. Parkinson's disease trial illustrates the dangers of stopping early.

K R Abrams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9552993      PMCID： PMC1112981          DOI： 10.1136/bmj.316.7139.1183

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

1.  When to stop a clinical trial.

Authors:  S J Pocock
Journal:  BMJ       Date:  1992-07-25

2.  Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.

Authors:  Y Ben-Shlomo; A Churchyard; J Head; B Hurwitz; P Overstall; J Ockelford; A J Lees
Journal:  BMJ       Date:  1998-04-18

3.  The statistical basis of public policy: a paradigm shift is overdue.

Authors:  R J Lilford; D Braunholtz
Journal:  BMJ       Date:  1996-09-07

4.  Bayesian interim analysis of randomised trials.

Authors:  K R Abrams; D R Jones
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

5.  Equipoise and the ethics of clinical research.

Authors:  B Freedman
Journal:  N Engl J Med       Date:  1987-07-16       Impact factor: 91.245

6.  Tutorial in biostatistics Bayesian data monitoring in clinical trials.

Authors:  P M Fayers; D Ashby; M K Parmar
Journal:  Stat Med       Date:  1997-06-30       Impact factor: 2.373

7.  Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.

Authors: 
Journal:  BMJ       Date:  1993-08-21

8.  Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

Authors:  A J Lees
Journal:  BMJ       Date:  1995-12-16

9.  Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.

Authors:  W Birkmayer; J Knoll; P Riederer; M B Youdim; V Hars; J Marton
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.